Zhejiang Zerui Biopharma Co.,Ltd.

Business Type:Manufacturer

Main Products:Semaglutide,Tirzepatide,Semaglutide main Chain / P29,Insulin Icodec,Retatrutide,BPC-157,Cagrilintide,Orforglipron,Somapacitan,Recombinant Kex2 Proteinase

Country/Region:China

Annual Revenue:2000000 USD

Main Markets:South America,Eastern Europe,Africa,Western Europe,

Ddu Verified

HOT Rank

6/10
Company Information

Zerui Biopharma Co., Ltd. (thereafter as Zerui Bio) was founded in 2020, bringing together a group of outstanding young talents in biopharmaceutical background. The company focuses on the technology platform of fermentation, purification as well as coupling reaction of peptides and proteins.

Following the trend of the development of biopharmaceutical industry, Zerui Bio has focused on the research and development of long-acting peptide and protein-coupled drugs, and built a strong product pipeline based on advanced technology platform.

In 2022, the company was granted as a small and medium-sized technology-based enterprise of Zhejiang Province. Zerui Bio own a 1000m² R&D center, 1000m² analysis laboratory center and 2000m² GMP standard pilot production workshop having the fermentation and coupling manufacturing facilities for the production of peptide API. From the design, the pilot production workshop built in the regulation requirements of CFDA, FDA and EMA to fulfill major drug markets in the world, to satisfy registration in domestic and overseas markets, so as to offer expertized service for our customers.

Zerui Bio provides peptide API manufactured in compliance with requirements of GMP to the global markets, as well as CDMO services of peptide API.

Email to this supplier
To

Send

Inquiry Cart(0)